bioRxiv Science⌕ Search

Biology subjects

Rougie, M.

Publications and source records attributed to Rougie, M..

2 recordsLinked to original sources

A membrane-permeable small molecule biosensor accesses intractable cells and animals without genetic manipulation

Fluorescent biosensors have proven valuable for revealing the spatio-temporal dynamics of protein conformation in live cells and animals. The great majority of biosensors are genetically encoded, but genetic encoding is difficult or impossible to apply in many cases, including cells or animals with poorly understood genomes, no DNA, or sensitive to manipulation. Using biosensors without genetic manipulation could greatly simplify studies in animals, expand the range of accessible organisms, and ultimately enable application in humans. Here we explore using a membrane-permeable small molecule as a fluorescent biosensor. The drug trifluoperazine, which binds only to the active conformation of calmodulin, was covalently linked to an environment-sensing merocyanine dye to create CaMero, a biosensor of calmodulin activation. Simple incubation of CaMero in the extracellular medium, or injection in the tail vein of mice, led to sensitive real time reporting of calmodulin activity. The dye underwent a 12-fold change in fluorescence intensity upon binding to activated calmodulin, revealing waves of activation in peristaltic intestine, localization and kinetics of calmodulin activation during serum stimulation in fibroblasts, and localized activation in the single-celled marine protist foraminifera.

cell biology↗

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice

Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are often refractory to existing antiepileptic medications. Therefore, there is an unmet need for better seizure control, which could potentially improve other symptomatic domains such as cognitive function. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has anti-seizure activity and behavioral benefits in preclinical and clinical studies for some disorders associated with epilepsy, suggesting that the same could be true for AS. Here we show that acute CBD (100 mg/kg) attenuated hyperthermia- and acoustically-induced seizures in a mouse model of AS. However, neither acute CBD nor a two-weeklong course of CBD administered immediately after a kindling protocol could halt the pro-epileptogenic plasticity observed in AS model mice. CBD had a mild sedative effect, but did not have a major impact on motor performance. CBD abrogated the enhanced delta rhythms observed in AS model mice, indicating that CBD administration could also help normalize the EEG deficits observed in individuals with AS. Our results provide critical preclinical evidence supporting CBD treatment of seizures and alleviation of EEG abnormalities in AS, and will thus help guide the rational development of CBD as an AS adjunctive treatment.

pharmacology and toxicology↗